Project Profile · IPA II · Competitiveness and Innovation
Direct Grant Project to Combat the COVID-19 Pandemic
Priority Area
Universities, public and private R&D institutes/centres, SMEs and large companies; other stakeholders in the vaccine and drug development R&D ecosystem; researchers affiliated with these institutions working on vaccine and drug development to fight COVID-19
Implementing Institution
Scientific and Technological Research Council of Türkiye (TÜBİTAK)
Partner Institutions
Health Institutes of Türkiye (TÜSEB)
Duration
30 months, 09.07.2021
EU Contribution
€8,000,000
Location
Ankara, Kocaeli
Project Objective
IPA II
The project aims to support research and development on vaccines and medicines, in the fight against the COVID-19 pandemic, within a platform where universities, public and private R&D organisations and private-sector companies work together.
Results Achieved / Expected Outputs
Expected Outputs
- 01 Financial support for the pre-clinical and clinical stages of vaccine and medicine development projects within the COVID-19 Türkiye Platform
- 02 Pre-clinical stages coordinated by TÜBİTAK and clinical stages by TÜSEB
Project profile · IPA II · Competitiveness and Innovation
All Competitiveness and Innovation Projects (IPA II)